Omega-3 Fatty Acids for Treatment of Major Depression

Omega-3 脂肪酸治疗重度抑郁症

基本信息

批准号：
7776936
负责人：
DAVID MISCHOULON
金额：
$ 34.41万
依托单位：
MASSACHUSETTS GENERAL HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2006
资助国家：
美国
起止时间：
2006-03-09 至 2012-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7776936
关键词：
Acids Acute-Phase Proteins Address Adhesives Adult Alternative Medicine American Heart Association Antidepressive Agents Apolipoproteins Arachidonic Acids Area Award Biochemical Biological Blood specimen Budgets C-reactive protein Cardiology Cardiovascular Diseases Cardiovascular system Cell membrane Characteristics Chronic Clinical Clinical Research Clinical Trials Collaborations Consumption Coordination and Collaboration Country Data Data Analyses Data Reporting Databases Depressed mood Depressive disorder Development Diet Dietary Supplementation Dietary intake Disease Disease remission Doctor of Philosophy Documentation Dose Double-Blind Method Eligibility Determination Epidemiology Erythrocytes Fatty Acids Fishes Food Functional disorder General Hospitals Goals Guidelines Hamilton Rating Scale for Depression Head Heart Diseases Human Resources Immune Immune system Immunologic Factors Immunologic Markers Incidence Individual Inflammatory Intake Interleukin-1 beta Interleukin-6 Lead Leadership Life Style Lipids Lipoproteins Literature Major Depressive Disorder Massachusetts Measurement Measures Mediating Mediation Mediator of activation protein Medical center Mental Depression Mentors Monitor Mood Disorders Moods National Center for Complementary and Alternative Medicine National Institute of Mental Health Natural Remedy Normal Range Omega-3 Fatty Acids Omega-6 Fatty Acids Orosomucoid Outcome Pathogenesis Pathway interactions Patients Persons Physiological Placebo Control Placebos Plasma Play Policies Polyunsaturated Fatty Acids Population Study Predisposition Preparation Prevalence Prevention therapy Principal Investigator Procedures Process Protein C Protocols documentation Psychiatry Publications Publishing Qualifying Quality Control Randomized Recording of previous events Recruitment Activity Relative (related person)Reporting Research Research Personnel Research Project Grants Rest Role Schedule Science Serum Shipping Ships Site Site Visit Societies Stress Supplementation Surrogate Markers Telephone Testing Textbooks Time Traction Training Tumor Necrosis Factor-alpha Visit Work Writing arm base cell type clinical practice clinically significant computerized data processing control trial cytokine design efficacy trial eicosapentanoic acid experience human TNF protein lipid metabolism meetings member programs psychoimmunology quality assurance response symposium treatment response

项目摘要

DESCRIPTION (provided by applicant): Convergent clinical and epidemiological data have implicated omega-3 (n-3) fatty acids in the pathophysiology, prevention, and therapy of common and disabling conditions such as major depressive disorder (MDD) and cardiovascular disease. The intake of omega-3 fatty acids in the western diet has decreased dramatically relative to omega-6 (n-6) intake over the past century, causing a substantial increase in the ratio of omega-6 to omega-3 (n-6:n-3). Coincident with this change in diet, the incidence of major depressive disorder has markedly increased in western societies. It has been postulated that the 21st century western urban lifestyle characterized by high stress, little rest, and high intake of processed (i.e. omega-6- rich) foods, creates a baseline "pro-inflammatory" predisposition that may contribute to the development of mood disorders in some individuals. As has been demonstrated in the cardiology literature, omega-3 administration may correct the n-6:n-3 ratio, and reverse this pro-inflammatory state. Recent controlled trials suggest that dietary supplementation with omega-3 fatty acids at doses about five or more times the standard dietary intake in the U.S. may yield clinically significant antidepressant and/or mood stabilizing effects; however, there is little known about the mechanism of action underlying this effect. There is also a paucity of data comparing and contrasting the relative antidepressant efficacy of the two main omega-3 fatty acids, eicosapentanoic acid (EPA) and docosahexanoic acid (DHA). This five-year collaborative R01 application will focus primarily on comparing the antidepressant efficacy of monotherapy with EPA vs. DHA vs. placebo. We will also investigate potential lipid and immunological mediators and moderators of n-3 fatty acid antidepressant response. Our study will be the first to address the relative antidepressant efficacy of EPA and DHA in a placebo-controlled head-to-head trial, and also the first to investigate the potentially important relationship between lipid metabolism, immune parameters, and response to n-3 dietary supplementation in major depression. This application is consistent with recent statements from the leadership of NCCAM and NIMH, emphasizing the importance of research that has "traction," i.e. integrates biological findings with treatment in order to have a direct impact on the clinical practice of psychiatry.

描述（由申请人提供）：收敛的临床和流行病学数据已涉及欧米茄-3（N-3）脂肪酸在病理生理学，预防和治疗常见和残疾状况（例如重大抑郁症（MDD）和心血管疾病）中的治疗。在过去的一个世纪，西方饮食中omega-3脂肪酸的摄入量相对于omega-6（N-6）的摄入量显着降低，从而导致omega-6与omega-3（n-6：n-3）的比率大幅增加。与这种饮食变化相吻合，西方社会的重度抑郁症的发生率显着增加。据推测，21世纪的西方城市生活方式的特征是压力很大，休息很少和高度摄入的加工（即omega-6-富集）食品产生了一种基线“促炎”的倾向，可能会导致某些人的情绪障碍的发展。正如心脏病学文献中所证明的那样，Omega-3给药可以纠正N-6：N-3比，并扭转这种促炎性状态。最近的对照试验表明，饮食中补充omega-3脂肪酸的剂量约五倍以上五倍以上的标准饮食摄入量可能会产生临床上显着的抗抑郁药和/或情绪稳定作用；但是，关于这种效果的作用机理鲜为人知。还缺乏比较和对比两种主要的omega-3脂肪酸，eicosapentanoic（EPA）和Docosahecahexanoic（DHA）的相对抗抑郁药疗效（DHA）的数据。这项为期五年的协作R01应用程序将主要集中于比较单一疗法与EPA与DHA与安慰剂的抗抑郁疗法。我们还将研究N-3脂肪酸抗抑郁反应的潜在脂质和免疫学介质和主持人。我们的研究将是第一个在安慰剂对照的头对头试验中解决EPA和DHA的相对抗抑郁药功效的研究，也是第一个研究脂质代谢，免疫参数和对N-3饮食补充剂的脂质代谢，免疫参数之间潜在重要关系的研究。该应用与NCCAM和NIMH领导的最新陈述是一致的，强调了具有“牵引力”的研究的重要性，即将生物学发现与治疗相结合，以直接影响精神病学的临床实践。

项目成果

期刊论文数量（4）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

The Impact of Omega-3 Fatty Acids on Depressive Disorders and Suicidality: Can We Reconcile 2 Studies With Seemingly Contradictory Results?

DOI：
10.4088/jcp.11com07463
发表时间：
2011-12-01
期刊：
JOURNAL OF CLINICAL PSYCHIATRY
影响因子：
5.3
作者：
Mischoulon, David
通讯作者：
Mischoulon, David

Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study.

DOI：
10.1038/mp.2015.22
发表时间：
2016-01
期刊：
Molecular psychiatry
影响因子：
11
作者：
Rapaport MH;Nierenberg AA;Schettler PJ;Kinkead B;Cardoos A;Walker R;Mischoulon D
通讯作者：
Mischoulon D

S-Adenosylmethionine (SAMe) for Neuropsychiatric Disorders: A Clinician-Oriented Review of Research.

DOI：
10.4088/jcp.16r11113
发表时间：
2017-06
期刊：
The Journal of clinical psychiatry
影响因子：
0
作者：
Sharma A;Gerbarg P;Bottiglieri T;Massoumi L;Carpenter LL;Lavretsky H;Muskin PR;Brown RP;Mischoulon D;as Work Group of the American Psychiatric Association Council on Research
通讯作者：
as Work Group of the American Psychiatric Association Council on Research